This newly discovered system operates via complexes of nanoparticles that, upon entering a cell, undergo a remarkable transformation. They acquire a specialized coating termed the “condensate corona,” a dense and stable droplet composed primarily of the cell’s own proteins and RNA molecules. These molecules are critical regulators of cellular functions, suggesting that the corona is not merely a passive shell but an active biological interface capable of conveying intricate biochemical information between cells.

What makes this cellular courier extraordinary is its possession of ‘keys’ that unlock endogenous biological gateways—natural entry points that were previously inaccessible using conventional delivery methods. This means the system can traverse formidable biological barriers within the body, reaching secluded or protected cellular environments that have historically been challenging to target with therapeutic agents. This capacity could revolutionize treatments for diseases requiring molecular intervention deep within cells or across complex tissue interfaces.

Associate Professor Yan Yan of UCD’s School of Biomolecular and Biomedical Science elaborated on the implications of this system: by exploiting these natural gateways, it becomes feasible to transport ‘toolkits’ composed of functional biomolecules such as proteins or RNA strands. These biomolecular messages could serve as extended corrective modules, enabling direct modification of cellular processes—opening avenues for precise RNA-, gene-, and protein-based therapies with enhanced efficacy and safety profiles.

The detailed investigation revealed that these condensate coronas not only form spontaneously but also encapsulate a distinct biological programme. Using innovative experimental setups, researchers embedded minute magnets within the nanoparticles, allowing them to capture and analyze the droplets mid-transit as they exited source cells en route to target recipient cells. Remarkably, the integrity of the biochemical messages remained intact throughout, providing unprecedented insight into the mechanics of message exchange at the cellular level.

Upon arrival at a new host cell, the condensate corona facilitates the detachment and intracellular release of its cargo. Unlike many synthetic delivery vehicles that are rapidly degraded or sequestered by the cell’s defense mechanisms, these biological couriers evade degradation with remarkable efficiency. This immune-evasive property ensures that the delivered biomolecules remain functionally active and can seamlessly integrate into the cellular milieu to effectuate their intended biological responses.

Professor Kenneth Dawson, leading the Centre for BioNano Interactions at UCD and a senior author of the study, highlighted the enigmatic nature of such natural communication systems: “We had long suspected the existence of natural couriers and gateways that permit specialized particulate transfer within organisms. Yet, pinpointing these useful particulates amidst the diverse and chaotically varied milieu of the body was akin to searching for a needle in a haystack.”

The research team’s ability to isolate these condensate corona–nanoparticle complexes signifies a potent breakthrough, enabling them not only to decode the native biological signals but also to hijack the system for therapeutic ends. By sending custom-engineered bio-messages through this natural channel, they envision a revolutionary shift in medical paradigms—from managing chronic, hard-to-treat diseases to potentially reversing them at a cellular communication level.

This discovery dovetails intriguingly with observations that malfunction or misdirection of this messaging system is implicated in pathological processes such as tumor metastasis. Thus, unraveling the foundational principles of this intercellular courier not only deepens fundamental biological understanding but also holds promise for novel cancer therapies targeting metastasis pathways.

The study’s success rests upon the interdisciplinary collaboration of experts at UCD’s Centre for BioNano Interactions, merging expertise in biomolecular science, nanoengineering, and biomedical research. This convergence enabled the design of advanced nanoparticle prototypes precise enough to negotiate biological landscapes and reveal hidden modes of cellular messaging previously masked by the complexity of biological systems.

Looking forward, the research sets the stage for engineering tailored nanoparticles capable of delivering sophisticated therapeutic payloads—including gene-editing tools, regulatory RNAs, or corrective proteins—to ultra-specific cellular compartments. Such precision delivery systems could redefine drug targeting, reduce off-target effects, and drastically enhance the safety profiles of treatments for a variety of genetic and degenerative diseases.

In summary, the identification and characterization of condensate corona–nanoparticle complexes mark a significant leap in nanomedicine and cell biology. By unveiling the natural pathways of biological messaging and exploiting their intrinsic targeting properties, the researchers have charted an innovative path toward next-generation therapies capable of crossing biological boundaries long deemed insurmountable.

This pioneering work not only enriches our comprehension of cellular communication mechanisms but also opens promising horizons for future biomedical interventions that harness and amplify the body’s own messaging infrastructures for transformative health outcomes.

Subject of Research: Cells
Article Title: Condensate corona–nanoparticle complexes transfer functional biomolecules between cells
News Publication Date: 16-Apr-2026
Web References: http://dx.doi.org/10.1038/s41563-026-02534-5
References: Nature Materials, DOI: 10.1038/s41563-026-02534-5
Image Credits: Not specified
Keywords: cellular communication, condensate corona, nanoparticles, biomolecules, RNA delivery, gene therapy, protein therapy, drug delivery, nanomedicine, intercellular messaging, biological gateways, tumour metastasis

Fungal infections, while often overlooked, can become life-threatening particularly for vulnerable populations, such as patients undergoing chemotherapy, organ transplant recipients, and individuals in intensive care. The Candida genus, which harmlessly cohabitates the human body, can quickly morph into pathogenic forms under certain conditions, leading to severe nosocomial infections. Among its species, Candida auris has emerged as a formidable adversary due to its ability to evade current antifungal treatments, a situation that has escalated alarmingly, with reported infections surging over 300% across the United States between 2017 and 2018 alone.

In tackling this pressing health issue, the research team at Brown has designed a specialized delivery system utilizing liposomes enhanced with targeting peptides. These peptides are short chains of amino acids chosen for their natural affinity to Candida cells, acting as a molecular GPS that guides the liposomes directly to the infection sites. Lead author Veronica LaMastro, a recent Ph.D. graduate in biomedical engineering, explained that this targeted delivery strategy significantly boosts both the specificity and effectiveness of antifungal agents, thus holding great promise against resistant strains.

The anatomical structure of these liposomes—spherical aggregates made from synthetic and organic lipids—enables them to encapsulate therapeutic agents within their lipid bilayers. By strategically decorating the liposomal surface with the peptide known as penetratin, the researchers have succeeded in amplifying their liposome’s binding affinity for Candida cells. This meticulous design resulted in notably improved interaction rates with the pathogens compared to conventional, non-targeted liposomes, confirming the potential of this targeting approach.

Evidence from extensive lab tests revealed compelling findings: the peptide-decorated liposomes not only excelled in targeting Candida cells but also delivered the ant fungal agent posaconazole with remarkable efficacy. This FDA-approved drug, traditionally utilized as a prophylactic against Candida overgrowth, when paired with the targeted liposomal system, achieved inhibitory concentrations up to eight times lower than previously required. Astonishingly, it demonstrated the ability to prevent biofilm formation at doses up to 1,300 times more effective than free posaconazole alone.

In the clinical context, Candida biofilms represent a significant challenge in treating infections, as these robust structures are notoriously resilient against conventional antifungal therapies and enable Candida to persist and propagate. By employing liposomes that deliver concentrated antifungal doses directly to biofilm sites, the research team posits substantial advancements in clinical treatment protocols.

To validate the therapeutic potential of their targeted liposomes in a living system, the team employed a mouse model of intradermal Candida albicans infections. Their findings underscored the promising utility of this novel delivery platform: mice treated with targeted liposomes exhibited a staggering 60% reduction in fungal burden compared to those receiving standard drug-loaded liposomes. These results illuminate a vital pathway forward in combatting the escalating threat posed by drug-resistant fungal pathogens.

As antifungal drug resistance continues to plague clinical medicine, the work spearheaded by Professor Anita Shukla and her colleagues at Brown’s School of Engineering emerges as a timely contribution to the field of biomedical engineering. Shukla emphasizes the critical need for innovation in the area of fungal research, especially given the rising tide of antimicrobial resistance.

This pioneering study not only provides insights into the mechanisms of enhanced antifungal targeting but also advocates for a broader exploration of similar targeted nanotechnology approaches across different infectious agents. The implications of these findings could reshape strategies in antifungal treatment, moving from conventional methodologies to cutting-edge, precision-targeted therapeutics.

Moreover, the research team is motivated to further refine and expand their platform. While their current study focused primarily on preventive measures using posaconazole, future investigations aim to adapt this innovative liposomal delivery mechanism for treating established fungal infections, potentially addressing a vast array of clinical scenarios.

The successful interplay between biotechnology and therapeutic application showcased in this study heralds a new era of antifungal innovation, underscoring the importance of specialized targeting in achieving effective treatment outcomes against resilient and often deadly fungal infections. Through continued examination of this methodology, researchers hope to further illuminate the pathways toward enhanced patient care and health outcomes in vulnerable populations grappling with the burden of opportunistic fungal infections.

These exciting developments signify a crucial pivot in our understanding of and approach to managing fungal infections, reinforcing the notion that innovative technology can provide solutions to longstanding medical challenges and improve the overall effectiveness of clinical interventions.

With the continued threat of Candida species exhibiting resistance to established treatments, this targeted peptide-decorated liposomal technology offers new avenues for discovery and application, urging a concerted effort from the scientific community to prioritize research in this vital field.

The study was funded by the National Science Foundation, highlighting the significance of supporting pioneering research aimed at addressing critical healthcare challenges. Moving forward, the research team remains committed to expanding the application of their novel technology, advocating for recognition of the pressing need to combat fungal infections with renewed vigor and innovation.

In summary, the emergence of this targeted liposomal system manifests a beacon of hope in the fight against fungal infections, paving the way for future advancements that can enhance the arsenal of treatments available to healthcare professionals facing mechanical resistance in clinical settings.

Subject of Research: Animals
Article Title: Peptide-Decorated Liposomes Enhance Fungal Targeting and Antifungal Drug Delivery
News Publication Date: 9-May-2025
Web References: Advanced Functional Materials
References: N/A
Image Credits: Credit: Shukla Lab / Brown University

Keywords

Fungal infections, Candida, liposomes, drug delivery, antimicrobial resistance, biofilms, nanotechnology, biomedical engineering, posaconazole.